DOT1L Inhibition Enhances Immunomodulatory Drug Response in Multiple Myeloma

Study Background and Research Question

Multiple myeloma (MM) remains a challenging hematological malignancy with limited long-term survival for a significant subset of patients, despite advances in immunotherapies such as immunomodulatory drugs (IMiDs), monoclonal antibodies, and CAR-T cell therapies. Epigenetic regulation, particularly through histone modifications, has emerged as a key factor in tumor progression and therapeutic resistance. The histone methyltransferase DOT1L, responsible for catalyzing methylation of histone H3 at lysine 79 (H3K79), has previously been implicated in transcriptional control and the survival of both leukemia and myeloma cells. The present study (Ishiguro et al., 2025) investigates whether DOT1L inhibition can reprogram innate immune signaling and potentiate the effects of IMiDs in MM, exploring both the mechanistic basis and therapeutic implications of this approach.

Key Innovation from the Reference Study

The key innovation of this work lies in its demonstration that DOT1L inhibition not only exerts direct anti-proliferative effects on MM cells, but also enhances type I interferon responses and increases expression of antigen presentation genes, thereby reprogramming the tumor's innate immune landscape. Most notably, the study uncovers a functional link between DOT1L inhibition and the activation of the STING-dependent DNA sensing pathway, which contributes to the anti-myeloma activity. Furthermore, the authors show that DOT1L inhibition synergistically enhances the efficacy of lenalidomide, an established IMiD, through upregulation of interferon-regulated genes (IRGs) and suppression of the IRF4-MYC oncogenic axis. These findings position DOT1L as a preferential epigenetic therapeutic target in MM and provide a rationale for combination strategies leveraging DOT1L inhibitors and immunomodulatory agents.

Methods and Experimental Design Insights

To dissect the epigenetic dependencies of MM, the authors utilized DepMap portal data to identify DOT1L as a critical survival factor among chromatin regulators in MM cell lines. Chemical inhibition of DOT1L was performed in vitro, coupled with transcriptomic profiling to characterize downstream gene expression changes. The team assessed the activation of immune pathways by evaluating type I interferon responses, HLA class II gene expression, and DNA damage signaling markers. Functional interrogation of the DNA sensing pathway was achieved using CRISPR/Cas9-mediated knockout of STING1, allowing for assessment of its role in mediating the immunologic and anti-proliferative effects of DOT1L inhibition. Finally, pharmacologic co-treatment experiments combined DOT1L inhibition with lenalidomide to evaluate synergy and downstream signaling effects, focusing particularly on the IRF4-MYC axis and expression of IRGs.

Core Findings and Why They Matter

The study reports several interrelated findings that advance the understanding of epigenetic-immune crosstalk in MM:

• DOT1L Dependency: MM cell survival is preferentially dependent on DOT1L compared to other epigenetic regulators (Ishiguro et al., 2025).
• Innate Immune Activation: DOT1L inhibition activates type I interferon signaling, upregulates interferon-regulated genes, and increases HLA class II gene expression, suggesting enhanced antigen presentation capacity.
• STING Pathway Involvement: The anti-myeloma effect and IRG induction from DOT1L inhibition are partially abrogated by STING1 knockout, indicating that DNA damage-induced activation of the cGAS-STING pathway mediates these responses.
• Transcriptional Repression of Oncogenic Axes: DOT1L inhibition downregulates IKZF1/3 and IRF4, both critical for MM cell survival and lenalidomide response.
• Enhanced Response to Lenalidomide: Combined DOT1L inhibition and lenalidomide treatment synergistically upregulate IRGs and suppress IRF4-MYC signaling, leading to greater anti-proliferative effects than either agent alone.

These findings underscore the dual role of DOT1L as a transcriptional regulator and immune modulator in MM, providing mechanistic support for targeting DOT1L in combination with immunotherapies to overcome resistance and improve clinical outcomes.

Comparison with Existing Internal Articles

Several recent articles provide additional context on the role of DOT1L inhibition in cancer and fibrotic disease models. For example, "Redefining Epigenetic Therapeutics" offers a strategic roadmap for using DOT1L inhibitors like EPZ5676 in MLL-rearranged leukemia, emphasizing their nanomolar potency and clinical promise in precision medicine. Similarly, "DOT1L Inhibitor EPZ-5676: Unveiling Innate Immunity Modulation" explores how DOT1L inhibition not only blocks H3K79 methylation but also modulates innate immune responses, bridging the mechanistic insights observed in leukemia with those now emerging in MM from the present study. Notably, studies such as "DOT1L Inhibition Mitigates Renal Fibrosis" highlight the cross-domain relevance of DOT1L as a target, though the current MM study is unique in establishing a direct link to immunomodulatory drug potentiation via STING pathway activation.

Limitations and Transferability

While the present study builds a compelling mechanistic framework for DOT1L inhibition in MM, several limitations should be acknowledged. Most mechanistic experiments were conducted in established MM cell lines, which may not fully recapitulate the immune and microenvironmental complexity of patient tumors. Although the dependence on DOT1L and the synergy with lenalidomide were robustly demonstrated, further in vivo validation and exploration of resistance mechanisms are warranted. Importantly, the specific features of the immune disruption in symptomatic MM patients may impact the translatability of these findings into clinical practice, as both innate and acquired immune responses are frequently compromised.

Protocol Parameters

• DOT1L inhibition exposure: In vitro studies typically employ DOT1L inhibitor concentrations in the low nanomolar range; for example, EPZ5676 exhibits an IC₅₀ of 0.8 nM against DOT1L (product information).
• Combination treatment timing: For synergy assessments, DOT1L inhibitor and lenalidomide are often co-administered for 48–72 hours in MM cell lines, with endpoint analyses for proliferation, apoptosis, and gene expression.
• CRISPR/Cas9-mediated knockout: Targeted knockout of STING1 or relevant signaling genes can clarify pathway involvement in IRG induction and anti-proliferative effects.
• Transcriptional profiling: RNA-seq or qPCR analysis is used to monitor IRG expression, HLA gene upregulation, and repression of the IRF4-MYC axis following DOT1L inhibition.

Research Support Resources

Researchers aiming to replicate or extend these findings can leverage highly selective DOT1L inhibitors in their workflows. EPZ5676 (SKU A4166) is a potent, SAM-competitive DOT1L inhibitor with demonstrated nanomolar activity and selectivity, supporting robust H3K79 methylation inhibition and reliable histone methyltransferase inhibition assays. For up-to-date protocols and additional epigenetic research insights, consult the referenced internal and external resources. APExBIO provides detailed product specifications and recommendations to facilitate advanced studies in DOT1L-dependent mechanisms.